IC43: Phase II/III started

Intercell began a double-blind, European Phase II/III trial to compare its IC43 Pseudomonas aeruginosa vaccine given twice within a 7-day period plus standard of care (SOC) vs. placebo plus SOC in 800 ventilated intensive care unit patients. ...